<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="246">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01138735</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18155</org_study_id>
    <nct_id>NCT01138735</nct_id>
  </id_info>
  <brief_title>Epiduo Pediatric Acne Study</brief_title>
  <official_title>A Multi-center, Randomized, Vehicle-controlled, Double-blind, Study to Evaluate the Safety and Efficacy of Epiduo速 (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Administered Once Daily for the Treatment of Subjects 9 to 11 Years of Age With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Epiduo速 (adapalene and
      benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to
      11 years of age with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Success Rate</measure>
    <time_frame>Baseline to Week 12 (Last Observation Carried Forward [LOCF])</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects rated Clear or Almost Clear with at least 2 grades reduction from Baseline on the Investigator's Global Assessment (IGA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Lesion Counts</measure>
    <time_frame>Baseline  to Week 12 (LOCF)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lesion Counts From Baseline</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Lesion Counts From Baseline</measure>
    <time_frame>Baseline to Week 12 (LOCF)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">285</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>adapalene/benzoyl peroxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epiduo速 (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Gel Vehicle applied topically once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adapalene/benzoyl peroxide</intervention_name>
    <description>daily topical application for 12 weeks</description>
    <arm_group_label>adapalene/benzoyl peroxide</arm_group_label>
    <other_name>Epiduo速 (adapalene and benzoyl peroxide) Gel 0.1%/2.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel Vehicle</intervention_name>
    <description>daily topical application for 12 weeks</description>
    <arm_group_label>Topical Gel Vehicle</arm_group_label>
    <other_name>Topical Gel Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of acne vulgaris with facial involvement

          -  Score of 3 (moderate) on the Investigator's Global Assessment (IGA) scale

          -  A minimum of 20 but not more than 100 total lesions (Noninflammatory and/or
             Inflammatory) on the face (including the nose) at Baseline

        Exclusion Criteria:

          -  Acne nodule or acne cyst

          -  Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.),
             or severe acne requiring systemic treatment

          -  Underlying diseases and/or dermatologic conditions that require the use of
             interfering topical or systemic therapy or that might interfere with study
             assessments

          -  Use of prohibited medications prior to the study and/or are unwilling to refrain from
             such use during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lorne Albrecht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guildford Dermatology Specialists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zoe Draelos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zoe Draelos, MD</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Eichenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital and Health Center Division of Pediatric and Adolescent Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boni Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAB Dermatology Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Fleischer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Flores, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FXM Research Miramar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Haber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haber Dermatology Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adelaide Hebert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Heffernan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Dermatology, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adult &amp; Pediatric Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kempers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Minnesota Clinical Study Center A Division of Associated Skin Care Specialist, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rodion Kunynetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ultranova Skincare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian Landells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nexus Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Lynde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lynderm Research Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Mader, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Associates of Kingsport, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lew Andrew Rosoph, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Bay Dermatology Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Schlessenger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Specialists, PC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Spigarelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Stein Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health Systems - Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Sugarman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redwood Family Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Werschler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Premier Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Westmoreland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palmetto Clinical Trial Services, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Zaenglein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State Milton S. Hershey Medical Center - Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Murakawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermcenter PC; Somerset Skin Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Dermatology Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Health Center Division of Pediatric and Adolescent Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Family Dermatology</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FXM Research Miramar</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adult &amp; Pediatric Dermatology</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems Department of Dermatology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermcenter PC - Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center A Division of Associated Skin Care Specialists, PA</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zoe Draelos, MD</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology - Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cininnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology Clinical Research Center</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center - Penn State College of Medicine</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Kingsport, PC</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Sciences Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guildford Dermatology Specialists</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1A 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skincare</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research, Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 4, 2013</lastchanged_date>
  <firstreceived_date>June 4, 2010</firstreceived_date>
  <firstreceived_results_date>February 19, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
